碱性磷酸酶治疗急性肾损伤的研究进展
本文综述碱性磷酸酶(ALP)治疗急性肾损伤(AKI)的机制与临床证据。动物研究提示ALP可减轻脂多糖诱导的炎症与肾损伤,但临床有效性尚未明确;作者提出ALP的抗炎作用可能不依赖对脂多糖的直接作用,并据此提出未来研究方向。
要点
- ALP治疗脓毒症相关AKI的临床有效性尚未得到明确证实
- ALP的保护作用可能通过阻断促炎受体激活、重定向细胞间信号及保护屏障组织实现
- 需重新评估ALP在实验室中获益的具体机制以确定其临床潜力
核心结论
- ALP作为AKI治疗策略的有效性尚未被明确证实,其真正临床潜力取决于对起保护作用的具体机制与通路的重新评估。
研究设计与样本
- 综述类文章,围绕ALP治疗AKI的机制与现有临床证据进行讨论,未报告系统检索范围与样本量。
主要发现
- 动物研究提示ALP对脂多糖诱导的炎症和肾损伤具有保护作用。
- ALP的抗炎特性可能并非依赖对脂多糖本身的直接作用,其他通路可能更为重要。
- ALP可阻止有害促炎受体的激活、重定向细胞间信号传导并保护屏障组织。
临床怎么用
- 目前不建议将ALP作为AKI的常规治疗,其应用应限于研究背景。
- 临床关注点应放在明确ALP获益的机制通路及设计验证性研究上。
局限性
- 综述未报告系统检索策略与纳入标准,证据以临床前研究为主。
- ALP治疗AKI的临床有效性尚缺乏确定性证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Through improved insights into the increasing incidence and detrimental effects of acute kidney injury (AKI), its clinical relevance has become more and more apparent. Although treatment strategies for AKI have also somewhat improved, an adequate remedy still does not exist. Finding one is complicated by a multifactorial pathophysiology and by heterogeneity in the patient population. Alkaline phosphatase (ALP) has been suggested as a therapy for sepsis-associated AKI because of its protective effects against lipopolysaccharide (LPS)-induced inflammation and kidney injury in animals. However, its effectiveness as an AKI treatment has not been demonstrated definitively. Because the anti-inflammatory properties of ALP are likely not reliant on a direct effect on LPS itself, we postulate that other pathways are much more important in explaining the renoprotective properties ascribed to ALP. The re-evaluation of which properties of the ALP enzyme are responsible for the benefit seen in the lab is an important step in determining where the true potential of ALP as a treatment strategy for AKI in the clinic lies. In this review we will discuss how ALP can prevent activation of harmful pro-inflammatory receptors, redirect cell-cell signalling and protect barrier tissues, which together form the basis for current knowledge of the role of ALP in the kidney. With this knowledge in mind and by analysing currently available clinical evidence, we propose directions for new research that can determine whether ALP as a treatment strategy for AKI has a future in the clinical field.
引用
- Steenvoorden TS, Rood JAJ, Bemelman FJ, et al. Alkaline phosphatase treatment of acute kidney injury-an update. Nephrol Dial Transplant. 2024. PMID: 38400561. doi:10.1093/ndt/gfae028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。